Drug resistance is an important problem in the treatment of hepatitis B virus infection, especially in cirrhotic patients. We don’t know the impact of all mutations which are occurring by selections of HBV variants during the treatment period. Here, we reported a patient diagnosed with HBV related cirrhosis and good clinical course even YMDD variants (L180M, M204I and additional V207I mutations) during the 8 years follow-up period of lamivudine treatment and HBV DNA became negative by additional adefovir dipivoxil therapy. This case showed V207I mutation has not associated with clinical deterioration in cirrhosis and adefovir dipivoxil is effective on V207I mutation.

Keywords: